BMS MANAGEMENT OF THE MENOPAUSE
CERTIFICATE LATEST UPDATED 2026-2027 ACTUAL
FINAL PRACTICE EXAM WITH ALL POSSIBLE MOST
TESTED 100 PRACTICE QUESTIONS AND 100%
CORRECT VERIFIED ANSWERS WITH DETAILED
RATIONALES PLUS CERTIFIED ANSWER KEY
RATED A+ MOST RECENT!!!
GOOD LUCK!!!
1. Which of the following is the most significant
risk factor for developing osteoporosis in a 60-
year-old woman?
A. Late menopause (after age 55)
B. Body mass index (BMI) of 28 kg/m²
C. Current use of hormone replacement therapy
D. Regular physical activity
E. Previous fragility fracture
Rationale: A prior fragility fracture is one of
the strongest independent risk factors for
future fractures. While early menopause is a
, risk factor, a previous fracture carries the
highest predictive value for subsequent
osteoporotic fractures.
2. A 48-year-old woman with a BMI of 34 kg/m²
requests HRT for severe menopausal symptoms.
Which route of oestrogen administration is
preferred and why?
A. Oral, due to better symptom control
B. Transdermal, due to lower risk of venous
thromboembolism (VTE)
C. Oral, due to a more favourable lipid profile
D. Transdermal, due to higher efficacy
E. Transdermal, due to lower risk of VTE in
obese women
Rationale: Obese women are already at an
increased baseline risk of VTE. Transdermal
oestrogen does not undergo first-pass hepatic
metabolism and is associated with a
significantly lower risk of VTE compared to oral
preparations, making it the preferred route in
women with a BMI > 30 kg/m².
,3. For a woman with an intact uterus on
continuous combined HRT, what is the
recommended timeframe for investigating
unscheduled bleeding?
A. Immediately, regardless of duration of use
B. After 3 months of treatment
C. After 6 months of treatment
D. Only if bleeding persists after 12 months
E. After 6 months or earlier if bleeding is heavy
or persistent
Rationale: The BMS guidelines recommend
that any unscheduled bleeding on continuous
combined HRT should be investigated if it
persists beyond 6 months of treatment, or
earlier if it is heavy, recurrent, or concerning,
to rule out endometrial pathology.
4. Which of the following is a characteristic
symptom of genitourinary syndrome of
menopause (GSM)?
A. Hot flushes
B. Night sweats
C. Mood swings
, D. Sleep disturbance
E. Dyspareunia
Rationale: Genitourinary Syndrome of
Menopause encompasses vulvovaginal
atrophy and lower urinary tract symptoms.
Dyspareunia, vaginal dryness, and irritation
are hallmark symptoms, whereas vasomotor
symptoms (flushes, sweats) and mood changes
are separate menopausal symptoms.
5. A 55-year-old woman has been on tibolone for
two years. She develops new-onset, persistent
right upper quadrant pain. Which of the
following is the most important next step?
A. Reassure her that this is a common side effect
B. Switch her to a different HRT preparation
C. Perform a liver function test and abdominal
ultrasound
D. Advise her to take the tibolone with food
E. Stop tibolone and investigate for gallbladder
disease
Rationale: Tibolone has been associated with
an increased risk of gallbladder disease. New-
CERTIFICATE LATEST UPDATED 2026-2027 ACTUAL
FINAL PRACTICE EXAM WITH ALL POSSIBLE MOST
TESTED 100 PRACTICE QUESTIONS AND 100%
CORRECT VERIFIED ANSWERS WITH DETAILED
RATIONALES PLUS CERTIFIED ANSWER KEY
RATED A+ MOST RECENT!!!
GOOD LUCK!!!
1. Which of the following is the most significant
risk factor for developing osteoporosis in a 60-
year-old woman?
A. Late menopause (after age 55)
B. Body mass index (BMI) of 28 kg/m²
C. Current use of hormone replacement therapy
D. Regular physical activity
E. Previous fragility fracture
Rationale: A prior fragility fracture is one of
the strongest independent risk factors for
future fractures. While early menopause is a
, risk factor, a previous fracture carries the
highest predictive value for subsequent
osteoporotic fractures.
2. A 48-year-old woman with a BMI of 34 kg/m²
requests HRT for severe menopausal symptoms.
Which route of oestrogen administration is
preferred and why?
A. Oral, due to better symptom control
B. Transdermal, due to lower risk of venous
thromboembolism (VTE)
C. Oral, due to a more favourable lipid profile
D. Transdermal, due to higher efficacy
E. Transdermal, due to lower risk of VTE in
obese women
Rationale: Obese women are already at an
increased baseline risk of VTE. Transdermal
oestrogen does not undergo first-pass hepatic
metabolism and is associated with a
significantly lower risk of VTE compared to oral
preparations, making it the preferred route in
women with a BMI > 30 kg/m².
,3. For a woman with an intact uterus on
continuous combined HRT, what is the
recommended timeframe for investigating
unscheduled bleeding?
A. Immediately, regardless of duration of use
B. After 3 months of treatment
C. After 6 months of treatment
D. Only if bleeding persists after 12 months
E. After 6 months or earlier if bleeding is heavy
or persistent
Rationale: The BMS guidelines recommend
that any unscheduled bleeding on continuous
combined HRT should be investigated if it
persists beyond 6 months of treatment, or
earlier if it is heavy, recurrent, or concerning,
to rule out endometrial pathology.
4. Which of the following is a characteristic
symptom of genitourinary syndrome of
menopause (GSM)?
A. Hot flushes
B. Night sweats
C. Mood swings
, D. Sleep disturbance
E. Dyspareunia
Rationale: Genitourinary Syndrome of
Menopause encompasses vulvovaginal
atrophy and lower urinary tract symptoms.
Dyspareunia, vaginal dryness, and irritation
are hallmark symptoms, whereas vasomotor
symptoms (flushes, sweats) and mood changes
are separate menopausal symptoms.
5. A 55-year-old woman has been on tibolone for
two years. She develops new-onset, persistent
right upper quadrant pain. Which of the
following is the most important next step?
A. Reassure her that this is a common side effect
B. Switch her to a different HRT preparation
C. Perform a liver function test and abdominal
ultrasound
D. Advise her to take the tibolone with food
E. Stop tibolone and investigate for gallbladder
disease
Rationale: Tibolone has been associated with
an increased risk of gallbladder disease. New-
